Skip to content

The Chinese Early-onset Hypertension Study (CHESS)

The Chinese Early-onset Hypertension Study (CHESS)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02819674
Acronym
CHESS
Enrollment
5000
Registered
2016-06-30
Start date
2012-10-31
Completion date
2020-12-31
Last updated
2018-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

hypertension, early onset, target organ damage

Brief summary

Hypertension (HTN) is the most important cardiovascular risk factor which is responsible for 50% of cardiovascular morbidity and mortality, and also a substantial public health problem affecting approximately 1/4 of the adult population in industrialized societies and over 1 billion people worldwide. Chronically elevated blood pressure without well control puts people at increased risk of target organ damages, including stroke, myocardial infarction, congestive heart failure, end-stage renal disease, blindness, and death. Especially, these damages are dramatically more severe in the early-onset hypertensive population.

Detailed description

In this study, the hypertensive individuals are consecutively recruited from multiple centers, with an early onset age (less than 40 when diagnosed). A complete clinical history (information on history of hypertension, demographic characteristics, personal and family medical history) are collected by a trained staff using a standardized questionnaire on the first day of baseline observation, and physical examination are also collected in a standard procedure. Blood samples are collected after 12-hour overnight fast and biological variables are determined. Genomic DNA is isolated from leukocytes according to a standard procedure. The individuals will receive follow-up in an ordinal system. The investigators will focus on the clinical and genetic features, genotype-phenotype correlations and influencing factors of prognosis in Chinese early-onset hypertension patients.

Interventions

None listed

Sponsors

China National Center for Cardiovascular Diseases
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* In accordance with the diagnosis of hypertension (BP≥140/90mmHg), and less than 40 years when diagnosed

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
primary mortality of early-onset hypertensionthrough study completion, an average of 5 yearsthe primary mortality of early-onset hypertension

Secondary

MeasureTime frameDescription
secondary outcomes of heartthrough study completion, an average of 5 yearsThe incidence rate of left ventricular hypertrophy, myocardial infarction, congestive heart failure, and arrhythmia.
secondary outcomes of brainthrough study completion, an average of 5 yearsThe incidence rate of stroke (include cerebral hemorrhage and cerebral ischemia)
secondary outcomes of kidneythrough study completion, an average of 5 yearsThe incidence rate of hypertensive renal injure and end-stage renal disease
secondary outcomes of eyesthrough study completion, an average of 5 yearsThe incidence rate of hypertensive eye injure

Countries

China

Contacts

Primary ContactLei Song, MD.& PhD.
clinicalfw@163.com86-13810532620
Backup ContactLei Song, MD.& PhD.
lsongqd@yahoo.com86-18600197655

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026